This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
Save the dateMarch 17–19, 2025 | Milan, Italy

Lilian Alcaraz
VP of Early Innovation Partnering at Johnson & Johnson Innovation


Lilian leads the London Innovation Centre’s Early Innovation Partnering team through the identification, incubation, due diligence, negotiations, execution and on-boarding of high-impact partnerships and collaborations for Johnson & Johnson, providing expert guidance on business strategy, sourcing, deal design, stakeholder management and governance. Lilian is also responsible for overseeing the management of the region’s partnership portfolio.

Lilian joined the LIC in 2015 as Sr. Dir. of Medicinal Chemistry working across all TAs and in 2016 he transitioned into the role of New Ventures and Transactions Lead for the Neuroscience TA, and then to Global Transaction Lead. He has experience in transacting across a wide range of collaboration and licensing opportunities, from small molecule and antibody asset deals, through to platform technologies, biomarkers, data science, and digital health applications.

Prior to joining J&J, Lilian gained over 18 years’ experience in Drug Discovery. Lilian was Sr. Dir. of Chemistry at Charles River and Galapagos (Argenta Discovery). Prior to that, Lilian spent 13 years at AstraZeneca advancing in various leadership roles in Respiratory and Inflammation TA. He has a long-standing passion for external innovation and collaborative partnerships.

Lilian received his Ph.D. in Organic Chemistry from Louis Pasteur University (Strasbourg, France), and was a Post-Doctoral Fellow at the University of York (UK). He has a certificate in Managerial Finance from the London School of Economics. Lilian is the author and co-author of 79 publications and patents, and of a book on Medicinal Chemistry. Over the years, he has been involved in the successful delivery of nine clinical candidates.

Agenda Sessions

  • Company creation in the current biotech market